Aspargo Laboratories, Inc. — Form D/A
Aspargo Laboratories, Inc. of ENGLEWOOD CLIFFS, NJ, a company, filed a Form D amendment with the SEC on 2020-10-15. The offering totals $8.5M, of which $7.9M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-10-15
- Form: D/A
- Accession: 0001753926-20-000335
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $8.5M
- Amount sold: $7.9M
- Remaining: $600K
- Minimum investment: $10K
- Investors: 290
- Date of first sale: 2020-02-02
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-361806
Issuer
- Name: Aspargo Laboratories, Inc.
- CIK: 0001805092
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 550 SYLVAN AVENUE, ENGLEWOOD CLIFFS, NJ, 07632
- Phone: 2014084831
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Michael Rice | Director | Bothell, WA |
| Fred Biehl | Director | Short Hills, NJ |
| Michael Demurjian | Director | Red Bank, NJ |
| Michael Demurjian | Executive Officer | Red Bank, NJ |
| Michael Demurjian | Promoter | Red Bank, NJ |
Other filings by this issuer (4)
More